Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987 Oct;336(4):409-14.
doi: 10.1007/BF00164874.

Inhibition of vasoconstriction to cirazoline by calcium-entry blockade after phenoxybenzamine in rat perfused hindquarters

Affiliations

Inhibition of vasoconstriction to cirazoline by calcium-entry blockade after phenoxybenzamine in rat perfused hindquarters

C Korstanje et al. Naunyn Schmiedebergs Arch Pharmacol. 1987 Oct.

Abstract

The effects of phenoxybenzamine and benextramine were assessed with respect to the vasoconstriction to cirazoline in rat perfused hindquarters. Experiments were performed with and without restriction of inward calcium flux by addition of nifedipine (10(-9)-10(-6) M) to the standard physiological solution (PS), or by omission of calcium chloride from the PS. Addition of nifedipine or omission of Ca2+ did not affect the maximal response or potency of the selective but partial alpha 1-adrenoceptor agonist, cirazoline in rat perfused hindquarters. Upon pretreatment with phenoxybenzamine (0.03-30 micrograms/kg, i.v. at -1 h) or benextramine (1 mg/kg, i.v. at -2 h) both the slope and the maximal response to cirazoline were depressed. After phenoxybenzamine but not after benextramine the maximal response to cirazoline was depressed further upon addition of nifedipine or omission of Ca2+ from the PS. It is concluded that phenoxybenzamine selectively inhibits that part of the alpha 1-adrenoceptor mediated vasoconstriction that is independent of extracellular calcium, thereby unmasking a calcium-entry sensitive mechanism of vasoconstriction to cirazoline.

PubMed Disclaimer

Similar articles

References

    1. Naunyn Schmiedebergs Arch Pharmacol. 1985 Jun;329(4):404-13 - PubMed
    1. Circ Res. 1983 Feb;52(2 Pt 2):I69-76 - PubMed
    1. J Pharmacol Exp Ther. 1984 May;229(2):515-21 - PubMed
    1. Eur J Pharmacol. 1983 Oct 14;94(1-2):171-4 - PubMed
    1. J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1102-8 - PubMed

LinkOut - more resources